Hannah Palac

ORCID: 0000-0003-1314-3329
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Neonatal Respiratory Health Research
  • Endometriosis Research and Treatment
  • Digital Mental Health Interventions
  • Mobile Health and mHealth Applications
  • Infant Development and Preterm Care
  • Rheumatoid Arthritis Research and Therapies
  • Mental Health Research Topics
  • Neonatal and Maternal Infections
  • Infant Nutrition and Health
  • Social Media in Health Education
  • Asthma and respiratory diseases
  • Inflammatory Bowel Disease
  • Microscopic Colitis
  • Autoimmune and Inflammatory Disorders Research
  • Inhalation and Respiratory Drug Delivery
  • Respiratory and Cough-Related Research
  • Transplantation: Methods and Outcomes
  • Cystic Fibrosis Research Advances
  • Childhood Cancer Survivors' Quality of Life
  • Pregnancy and preeclampsia studies
  • Chronic Lymphocytic Leukemia Research
  • Renal Transplantation Outcomes and Treatments
  • Patient-Provider Communication in Healthcare
  • Spondyloarthritis Studies and Treatments
  • Adenosine and Purinergic Signaling

AbbVie (United States)
2018-2025

Northwestern University
2015-2020

Lurie Children's Hospital
2015-2020

Yale University
2019

Behavioral Tech
2015-2018

RELX Group (United States)
2018

University of Wisconsin–Madison
2015

Background: Digital mental health tools have tended to use psychoeducational strategies based on treatment orientations developed and validated outside of digital health. These features do not map well the brief but frequent ways that people mobile phones phone apps today. To address these challenges, we a suite for depression anxiety called IntelliCare, each with focused goal interactional style. IntelliCare prioritize interactive skills training over education are designed short interactions.

10.2196/jmir.6645 article EN cc-by Journal of Medical Internet Research 2017-01-05

To evaluate the long-term safety profile for upadacitinib across rheumatoid arthritis (RA), psoriatic (PsA), ankylosing spondylitis (AS) and atopic dermatitis (AD).Safety data from clinical trials of 15 mg 30 (AD only) treating RA, PsA, AS AD as June 2021 were analysed; some RA PsA studies included adalimumab methotrexate active comparators. Treatment-emergent adverse events (TEAEs) presented by disease exposure-adjusted event rates per 100 patient years (E/100 PY).The analysis 6991 patients...

10.1136/rmdopen-2022-002735 article EN cc-by-nc RMD Open 2023-02-01

Increased risk of serious adverse events (AEs) was reported for tofacitinib relative to tumour necrosis factor inhibitor therapy in patients with rheumatoid arthritis (RA) aged ≥50 years enriched cardiovascular (CV) (ORAL Surveillance). We assessed post hoc the potential upadacitinib a similar RA population.Pooled safety data from six phase III trials were evaluated AEs receiving 15 mg once day (with or without conventional synthetic disease-modifying antirheumatic drugs), adalimumab 40...

10.1136/ard-2023-223916 article EN cc-by-nc Annals of the Rheumatic Diseases 2023-06-12

Upadacitinib is indicated for diseases affecting persons of childbearing potential including rheumatoid arthritis, psoriatic axial spondyloarthritis, atopic dermatitis, Crohn's disease, and ulcerative colitis; however, teratogenicity was observed in animal studies. Given the human fetal risk, pregnancy avoidance measures were required during clinical trials. This analysis describes outcomes patients exposed to upadacitinib pregnancy. Clinical trial postmarketing cases utero exposure...

10.1007/s40264-024-01454-0 article EN cc-by-nc Drug Safety 2024-07-15

Background Early onset sepsis (EOS) is a major cause of morbidity and mortality in preterm infants, yet diagnosis remains inadequate resulting missed cases or prolonged empiric antibiotics with adverse consequences. Evaluation acute phase reactant (APR) biomarkers umbilical cord blood at birth may improve EOS detection infants intrauterine infection. Methods In this nested case-control study, (29.7 weeks gestation, IQR: 27.7–32.2) were identified from longitudinal cohort archived placental...

10.1371/journal.pone.0168677 article EN cc-by PLoS ONE 2017-01-03

Abstract Objective SCN2A ‐associated developmental and epileptic encephalopathies (DEEs) present with seizures, impairments, often both. We sought to characterize the level pattern of development in children variants, address sensitivity Vineland Adaptive Behavior Scales (VABS) measuring changes over time ‐DEEs. Methods Clinical histories for participants pathogenic variants Simons SearchLight project were analyzed descriptive purposes. VABS scores obtained at study entry yearly thereafter...

10.1111/epi.16750 article EN Epilepsia 2020-11-25

Objectives To provide an integrated analysis of major adverse cardiovascular events (MACEs) and venous thromboembolism (VTE) associated risk factors across rheumatoid arthritis (RA), psoriatic (PsA), ankylosing spondylitis (AS) phase 2b/3 upadacitinib clinical programmes. Methods Data were analysed summarised from trials RA, PsA AS treated with 15 mg once daily (QD) 30 QD (as June 2021). adalimumab (RA PsA) methotrexate (RA) arms included as comparators. Adjudicated MACEs VTE presented...

10.1136/rmdopen-2023-003392 article EN cc-by-nc RMD Open 2023-11-01

Major depressive disorder is a common psychological problem affecting up to 20% of adults in their lifetime. The majority people treated for depression receive antidepressant medication through primary care physician. This commonly results low rates recovery. Failure points the process contributing poor outcomes include patient non-adherence medications, failure physicians optimize dose and absence communication between patients physicians.This pilot study evaluated feasibility systemic...

10.1177/2055207616663069 article EN cc-by-nc-nd Digital Health 2016-01-01

This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated upadacitinib (UPA) active comparators. integrated safety analysis includes data from 11 phase 3 UPA trials across RA (6 trials), PsA (2 AS trials; one 2b/3), and nr-axSpA (1 trial). Treatment-emergent adverse events (TEAEs) were summarized for (pooled 15 mg [UPA15], pooled 30 [UPA30], adalimumab 40...

10.1007/s40744-023-00621-6 article EN cc-by-nc Rheumatology and Therapy 2023-11-20

The development of pulmonary hypertension (PH) is a serious complication bronchopulmonary dysplasia (BPD) among infants born at extremely low gestational ages. Bronchopulmonary dysplasia-associated PH characterized by persistent vasoconstriction, progressive right heart dysfunction, and an increased risk death. We have shown previously that certain placental vascular lesions are associated with BPD-associated PH. Further evaluation the villous morphometry these placentas warranted. Using...

10.2350/15-05-1646-oa.1 article EN Pediatric and Developmental Pathology 2015-09-14

Background: The ability to successfully recruit participants for electronic health (eHealth) clinical trials is largely dependent on the use of efficient and effective recruitment strategies. Determining which types strategies presents a challenge many researchers. Objective: aim this study was present an analysis time-efficiency cost-effectiveness eHealth trials, it describes framework cost-effective trial recruitment. Methods: Participants were recruited one 5 interventions common mental...

10.2196/11050 article EN cc-by Journal of Medical Internet Research 2018-09-10

Major depression is common, and imposes a high burden in terms of cost, morbidity, suffering. Most people with are treated general medicine using antidepressant medication. Outcomes poor due to failure points across the care system, including patient non-adherence, physicians optimize treatment regimens, lack patient-physician communication. This study reports on 4-week pilot deployment MedLink, mobile intervention aimed at systemically addressing each these points. A app provides...

10.4108/icst.pervasivehealth.2015.259042 article EN cc-by EAI Endorsed Transactions on Pervasive Health and Technology 2015-08-03

Kawasaki disease (KD) shock syndrome (KDSS) is hypotension with KD. We compared children KDSS and matched control Children more often were female, had a lower platelet count sodium concentration, condition refractory to immunoglobulin, abnormal echocardiography results. unique subset of

10.1093/jpids/piw081 article EN Journal of the Pediatric Infectious Diseases Society 2016-11-23

Past studies have not evaluated inhaler use in hospitalized children with asthma. The objectives of this study were to evaluate technique pediatric patients asthma and identify risk factors for improper use. We conducted a prospective cross-sectional tertiary children's hospital 2-16 years age admitted an exacerbation, demonstrations analyzed. Of 113 participants enrolled, 55% had uncontrolled asthma, 42% missed critical step technique. More when they used spacer mouthpiece instead mask (75%...

10.12788/jhm.3195 article EN Journal of Hospital Medicine 2019-04-08

The content of pediatric hospital discharge instructions is highly variable. This study aimed to describe the characteristics, accessibility per patient literacy level and language, national guideline adherence instructions.This retrospective assessed at a tertiary children's hospital. Patient instruction including health level, grade instructions, language preference, were collected via chart review electronic medical record query. Standard admission processes Brief Health Literacy...

10.1542/hpeds.2021-006493 article EN Hospital Pediatrics 2022-10-05
Coming Soon ...